Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XWELL Inc

The TGS program, a leading example of biosecurity infrastructure, operates at a total of nine US locations and leverages voluntary nasal swabs as well as wastewater sampling from international travelers to detect more than 30 pathogens. BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

AbbVie

Pfizer

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

3 Pharmaceutical Stocks to Buy Hand Over Fist in March

Ginkgo Bioworks is aiming to play a key role in drug development. And there's a solid argument for why it could be hugely successful one day.

Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2023 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates

$251 million of Total revenue in 2023 $139 million in Cell Engineering services revenue, representing 31% growth over 2022 78 new Cell Programs added in 2023, representing 32% growth over 2022 and continued penetration in biopharma Year-end cash balance of nearly $950 million provides meaningful multi-year runway as we drive towards profitability and begin recognizing benefits from improved platform efficiency BOSTON , Feb. 29, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2023. The update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results

Investors can learn a lot by observing how corporate insiders handle positions in their own companies.

CEO Dumps 20 Million Ginkgo Bioworks Shares

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- #Celltherapy--bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network. The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer.

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks' New Technology Network

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced that in connection to its transaction with Patch Biosciences, Inc. ("Patch Bio") on February 26, 2024, Ginkgo approved grants of restricted stock units with an aggregate grant date fair value of  $4,292,000 to eight Patch Bio employees, and in connection with its acquisition of Reverie Labs, Inc. ("Reverie") on February 23, 2024, Ginkgo approved grants of restricted stock units with an aggregate grant date fair value of $3,530,000 to four Reverie employees. The restricted stock units were granted without stockholder approval as material inducements to the employees entering into employment with Ginkgo pursuant to NYSE Listed Company Manual Section 303A.08 and were approved by the compensation committee of Ginkgo's board of directors.

Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery. Ginkgo has acquired Reverie's infrastructure and software for training large-scale AI foundation models and four of Reverie's key AI team members will join Ginkgo.

Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases. Proof was founded by gene editing pioneer Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs.

Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences , which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32. The acquisition is intended to strengthen Ginkgo's Gene Therapy Services , Cell Therapy Services , and RNA Therapeutics Services.

Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets Based on strong initial customer feedback, Ginkgo expects to add new partners to the network over time, expanding this integrated offering and helping eliminate the siloing and switching costs that limit R&D progress today BOSTON , Feb. 28, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the creation of the Ginkgo Technology Network - a groundbreaking ecosystem of cutting edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs. For over 15 years, Ginkgo has invested in building and integrating horizontal platform technologies to serve a diverse set of customer programs and needs with efficient and powerful services.

Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners

The center will be a first of its-kind collection and analysis center for data gathered through Ginkgo's pathogen monitoring network DOHA, Qatar , Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has announced today the signing of an agreement with Qatar Free Zones Authority (QFZ) and Doha Venture Capital (DVC) to build the first Center for Unified Biosecurity Excellence in Doha (CUBE-D) within Qatar Free Zones. The signing took place alongside QFZ's and DVC's participation in the Web Summit Qatar, in a ceremony attended by HE.

Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones

BOSTON , Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to participate in Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:10 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Participation in the 44th Annual TD Cowen Health Care Conference

Ginkgo's cell programming process helps businesses launch products and improve existing processes. The company has partnered with many top names in the healthcare industry for this purpose.

Is Ginkgo Bioworks Stock a Buy Now?

Iovance Biotherapeutics

Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.

2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value

Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024 BOSTON , Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation

Agenus

BOSTON and LEXINGTON, Mass. , Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc. (NYSE: DNA) and SaponiQx, Inc. (a subsidiary of Agenus Inc., NASDAQ:AGEN) to discover and develop next-generation vaccine adjuvants.

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

Archer Aviation

Pacific Biosciences of California

Pinterest

Palantir Technologies

Rocket Lab USA

Twist Bioscience Corp

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

7 Stocks Cathie Wood Is Still Loading Up On in Q1

Members of Congress visited Ginkgo's Boston Seaport headquarters to discuss strategies for bolstering U.S. ability to compete in AI applications for biotechnology, as well as unlocking innovations in pharmaceuticals, agriculture, and across industries Ginkgo's Foundry generates essential data assets and tools to allow companies to more reliably develop biotech products  Members also previewed Ginkgo's new Biofab1 facility, under construction in the Seaport, which is expected to significantly increase Ginkgo's R&D-for-service capacities when fully operational Ginkgo's facilities in Boston encompass 500,000+ sq. ft. of existing and planned capacity.

House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025

Recursion Pharmaceuticals

Cathie Wood is known for investing in cutting-edge technologies. These two biotech stocks hold a fascinating long-term value proposition, thanks to their use of artificial intelligence and other groundbreaking technologies.

2 Cathie Wood Stocks With Jaw-Dropping Growth Potential

CRISPR Therapeutics

Cathie Wood has been investing in a few advanced biotechs lately. She's displaying particular interest in automation-heavy biotechs.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You?

KETCHUM, Idaho , Feb. 1, 2024 /PRNewswire/ -- Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United States. With support from notable biotech leaders such as NFX and Ginkgo Bioworks (NYSE: DNA), Light Bio is reimagining the horticultural industry by introducing a new category of plants that emit an ethereal glow to enrich homes, gardens, and public spaces.

Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval

This first milestone has made the full color palette of the yellow-to-purple spectrum accessible for Phytolon's food colors and has further established a unique and cost-efficient offering for the food industry Phytolon's natural betalain pigments, produced through fermentation-based technologies, offer safe, sustainable alternatives to synthetic dyes, addressing growing regulatory concerns and consumer demand for natural products Ginkgo Natural Product Services played a crucial role in enhancing the efficiency of Phytolon's yeast strains, ensuring the consistent and robust production of sustainable food colors via two producing strains YOKNE'AM ILLIT, Israel and BOSTON , Jan. 31, 2024 /PRNewswire/ -- Phytolon, a biotechnology company that offers natural food colors via fermentation-based technologies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of the first development milestone of their multi-product collaboration to produce natural food colors and the resulting distribution of an equity milestone to Ginkgo. Ginkgo and Phytolon's partnership, which began in February 2022, aims to produce vibrant betalain pigments spanning the entire yellow-to-purple spectrum using cell engineering.

News for Ginkgo Bioworks Holdings Stock (DNA)